Filing Flows › Royalty Pharma (RPRX) › Net income
Royalty Pharma (RPRX) net income by quarter
Royalty Pharma's net income was $145M in Q3 2026 (third quarter 2026), +709% from Q2 2026. Over the last 7 quarters it ranged from $17.9M (Q2 2026) to $295M (Q1 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $145M | +709% | -49% |
| Q2 2026 | $17.9M | -94% | -41% |
| Q1 2026 | $295M | +37% | +23% |
| Q4 2025 | $215M | -24% | — |
| Q3 2025 | $284M | +842% | — |
| Q2 2025 | $30.2M | -87% | — |
| Q1 2025 | $239M | — | — |
Q3 2026 at a glance
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart follows the revenue to costs, profit and cash.
Questions
What is Royalty Pharma's net income?
Royalty Pharma's net income was $145M in Q3 2026 (third quarter 2026), +709% from Q2 2026.
How has Royalty Pharma's net income changed?
Over the last 7 quarters it ranged from $17.9M (Q2 2026) to $295M (Q1 2026).